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Susceptibility of coagulase-negative staphylococci to 
teicoplanin 
Clin Microbiol Infect 1996; 2: 000-000 
Coagulase-negative staphylococci (CNS) provide an 
increasing challenge in medicine, arising from their 
association with deep seated infections - often com- 
plicated by foreign bodies - and their resistance to 
commonly used antibiotics. The use of wide-spectrum 
agents in ‘decontamination’ for those at risk of systemic 
infections often selects CNS, for which intravascular 
access lines provide a convenient portal of entry. CNS 
infections demand therapy with a glycopeptide anti- 
biotic such as vancomycin or teicoplanin. However, 
both the terms ‘coagulase-negative staphylococci’, and 
‘glycopeptide’ cover agents with differing properties. 
As identification kits are expensive, the umbrella 
term CNS for organisms which are usually regarded as 
normal skin flora or contaminants in blood cultures has 
been much used. Nonetheless, identification of CNS 
to species level is important. Strains of Staphylococcus 
epidermidis, especially the slime-producing strains, 
are the commonest pathogenic CNS. Slime allows 
attachment to indwelling medical devices, is associated 
with more general resistance to antibiotics [I] and 
can antagonize glycopeptides [2]. Slime producers 
are usually S. epidermidis but occasionally Staphylococcus 
haemolyticus. Surveys show S. haemolyticus to be the 
second commonest pathogen - isolated particularly 
from patients with bacteremia [3,4], sometimes follow- 
ing nosocomial spread. 
Teicoplanin and vancomycin have similar structures 
but different antimicrobial and pharmacokinetic 
properties [5]. The lipophilic activity of teicoplanin 
may account for the difference. While both bind to the 
sticky d-Ma-d-Ma terminal chains of nascent peptido- 
glycan, vancomycin forms a dimer, while teicoplanin 
binds as a monomer [6]. In vitro tests for the suscepti- 
bility of CNS to teicoplanin have been problematic for 
two reasons: the effect of the medium used, and the 
poor diffusion of the large molecule in solid media. 
Felmingham et al. [7] found that the MIC varied 
with inoculum size and medium (e.g. 0.7 pg/mL on 
Isosensitest agar to 2.1 pg/mL. on Diagnostic Sensitivity 
Test [DST] medium). Others have reported poor 
correlation between tube-dilution MICs and disk 
susceptibility tests [8] even after increasing disk 
concentrations from 30 to 120 mg/L [9]. The NCCLS 
recommends a breakpoint of 232 mg/L for resistance 
[lo]. Most strains of CNS are susceptible according to 
this standard, but resistance has been encountered; 
Goldstein et al. [l 11 reported a rate of 1.7%. Resistance 
has been found in some strains of S. haemolyticus which 
are less susceptible to teicoplanin than vancomycin, 
although reference strains are susceptible [12]. Teico- 
planin resistance has been generated in S. haemolyticus 
laboratory strains [13], and reported as emerging in two 
strains of S. haemolyticus and one of S. epidermidis in 
neutropenic patients treated for bacteremia with the 
low dose of 200 mg teicoplanin daily [14]. Twenty- 
seven resistant strains of S. epidermidis were reported 
from France [ 151. 
In this context it is useful to review our own data 
from Papworth Hospital, Cambridge, UK. A study 
of wound infection following open-heart surgery 
[ 161 accompanied by perioperative prophylaxis with 
cloxacillin and gentamicin showed that cultures from 
inflamed but not frankly purulent wounds frequently 
grew CNS, which were regarded as contaminants. 
Archer and Armstrong [17] studied CNS on patients’ 
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skm following open-heart surgery and noted that 
following cefazolin prophylaxis methicillin-resistant 
strains were found in over 50% of patients. They 
attributed this to nosocomial spread. In view of the 
possible clinical significance of CNS in some wound 
infections, we repeated our study and examined the 
activity of glycopeptides with particular reference to p- 
lactam-resistent strains [18]. Skin swabs were taken 
from multiple sites on 120 patients and cultured on 
nutrient agar with and without methicillin (4 mg/L). 
CNS were recovered from 808/1085 swabs. Ifpossible, 
five simdar colonies of CNS from the methicillin plate 
were inoculated into broth - if there was no growth, 
then five colonies were selected from the antibiotic-free 
medium. Broth subcultures were used (lo4-’ CFU/ 
spot) for agar dilution MIC tests on Isosensitest agar 
(Oxoid) of vancomycin and teicoplanin, with added 
4% polyvinylpyrrolidone for flucloxacillin. Cultures 
were biotyped using a multipoint system with tests for 
coagulase, DNAse and novobiocin susceptibility, and 
for fermentation of fructose, mannose, lactose, maltose, 
trehalose, mannitol, xylose and sucrose. Seven hundred 
and eighteen isolates were tested. The commonest 
type was S. epidermidis (283 strains) but, surprisingly, S. 
simulans (85) came next, followed by S. haemolyticus 
(78). The MIC 90% of both vancomycin and teico- 
planin was 2 pg/mL and of flucloxacillin was 1 pg/mL 
(Table 1). However, when strains with MICs above 
these values were examined, an interesting pattern 
emerged with respect to time of isolation and biotype. 
Twenty-seven isolates with a vancomycin MIC of 
4 pg/mL. were obtained from 12 patients; they were 
scattered in time of isolation, with nine coming from 
pre-operative swabs. Five isolates were ‘mixed’, 14 were 
S. epidermidis and eight were S. haemolyticus. Thirty-six 
isolates with a teicoplanin MIC of 2 4  pg/L were 
obtained from 30 patients; 10 were from preoperative 
swabs. Eight isolates were ‘mixed’, 21 were S. huemo- 
lyticus, five S. simu!ans and two S. warneri. Only three 
strains, all of S. haemolyticus, were found in both pre- 
and postoperative swabs. None had an MIC >8 pg/mL 
and all would have been regarded as susceptible. The 
methicillin-resistant staphylococci presented a totally 
different picture. Eighty-nine isolates (&om 50 patients) 
had an MIC >2 pg/mL to flucloxacillin; only 13 came 
Table 1 MICs of test antimicrobial agents 
MIC 50‘% MIC 90% Range 
Teicoplanin 0.5 2.0 4 . 0 6  to 8 
Vmcomycin 1 .0 2.0 4 . 0 6  to 4 
Flucloxacillin 0.25 8.0 <0.03 to >32 
Chlorhexidine 4.0 8.0 0.5 to >32 
Numbers: MIC of stated antibiotic in pg/mL. 
from preoperative swabs. Twenty isolates were ‘mixed,’ 
18 were S. epidermidis, 40 S. simulans, six S. haemolyticus, 
two S. capitis, two S. saprophyticus and one S. horninis. 
Fifty-nine isolates were highly resistant (MIC >32 
p g / d ) ,  including 32 of S. simulans. Only nine isolates 
came from preoperative swabs, of which two were S. 
simulans. 
A prime reason for using glycopeptides is the 
increasing importance of methicihn-resistant staphylo- 
cocci, and our study confirmed that of Archer and 
Armstrong [17] on emergence of resistance in skin flora 
after cardiac operations. Although the numbers of 
bacteria tested constituted a minute sample, a signifi- 
cant phenomenon was observed: the finding of highly 
methicillin-resistant S. simulans strains, which, as they 
were nearly all from postoperative swabs, implied 
nosocomial spread. This suggestion is supported by the 
observation that the isolates were a similar subtype; 
(mannose negative), with decreased susceptibility to 
chlorhexidine (used for preoperative skin preparation). 
The clinical relevance of S. simulans remains to be 
evaluated. Since the study a special watch has been kept 
for S. simulans in clinical specimens and it has been 
isolated in pure culture from both blood and from 
sternal wound tissue on occasion. Perhaps the purity 
of the culture is explicable by the production of 
lysostaphin as well as p-lactamases [19]. 
Glycopeptide antibiotics were effective against our 
isolates whether p-lactam resistant or not. Strains with 
an MIC above the ofvancomycin or teicoplanin 
were isolated at random from pre- or postoperative 
samples, and were definitely not hospital acquired. Our 
findings confirmed earlier reports on teicoplanin, 
which was more active than vancomycin against most 
CNS (except S. haemolytirus); recent studies using the 
NCCLS method show similar activity (Table 2). 
Nosocomial spread of CNS in a cardiac surgery 
unit was reported from Rhode Island. This involved the 
spread of a single strain of S. epidermidis involving 10 
patients. Plasmid profiles and EcoRI restriction enzyme 
endonuclease digest patterns were used to fingerprint 
the strain, the source of which was a cardiac surgeon 
who carried it on his hands [20]. Other units have 
clearly had problems with nosocomial S. haemolyticus 
[4], and a survey ofthe Bristol cardiac unit [21] revealed 
this species (teicoplanin MIC 8 to 32 pg/mL) in one 
patient, one staff member and the environment, 
although it had not caused any clinical problems. 
The extensive teicoplanin literature throws up 
some paradoxical data. Susceptibility testing has created 
problems relating to both the techniques involved, and 
the relevance of the results to clinical outcomes. The 
laboratory data certainly include teicoplanin-resistant 
strains of S. huemolyticus and occasionally S. epidermidis 
N o t e s  a n d  C o m m e n t s  1 5 7  
Table 2 MICs of teicoplanin and vancomycin for CNS 
Teicoplanin Vanconiycin _~ 
Strain No. 50% 90% 50%) 90%) Ref. 
S .  rpidermidis 15 8 8  2 2 25 
S. I/oemolyticitc 15 16 32 2 2  
S. epidcrmidic-r 64 2 4  2 4  
s. Iraemulyrirus-5 5 1 2  1 1  
S. Iraemolyticirs-r 6 4 8  2 2  
S. cpidermidis-s 43 2 4  2 4 26 
S. epidermidir-s 60 0.25 1 1 1 27 
S. lrorriinis 23 1 2  1 1  
S. haemolyritnr 16 2 4  1 1  
S. cpidermidi.c-s 55 1 2  1 2 28 
S. epidrrmidis-r 58 4 8  1 2  
S. /iaemolyticus-< 10 1 4  1 2  
S. liaemolytict~r-r 29 8 32 1 2  
s = niethicillin/oxacillin susceptible; r = methicillin/oxacillin 
resistant. 
and the ability to generate resistance in vitro, although 
the clinical relevance of these observations remains 
unclear. A 3 mg/kg per day teicoplanin dosage schedule 
was clearly too low, but a summary of the outcome of 
teicoplanin therapy for CNS from early open studies in 
the UK and France [22] revealed that 34 of 39 patients 
with CNS infections treated with nionotherapy in 
adequate dosage responded and that response did not 
correlate with the organism’s susceptibility to teico- 
planin. The results of comparative clinical trials with 
larger doses are beginning to appear and show no 
significant difference between the therapeutic values of 
teicoplanin or vancomycin. In a major phase 111 trial 
from Italy comparing ceftazidime and amikacin with 
either vancomycin or teicoplanin for treatment of fever 
in neutropenia [23], CNS were found as single agents 
in the blood of 43 out of 527 emluable patients. The 
response rate to both agents was identical (81% cure). 
Addition of rifampicin may be of value when dealing 
with resistant stains [24], and teicoplanin can reduce the 
emergence of rifampicin resistance. 
S. W B. Newsom 
Papworth Hospital, 
Cambridge CB3 8RE 
United Kingdom 
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